Boubakar Ba
University Lecturer
ADH

 

Surname / Name : Boubakar dit Bayla BA, Ph. D, Pharm. D, Assistant Professor, Hors Classe

Email : boubakar-dit-bayla.ba@u-bordeaux.fr

Career history. Pharmacokinetic analyst, Boubakar B. BA hold from the University of Marseille, a Ph. D in Pharmacology, Basic and Clinical Pharmacokinetic Option in 1988. During the preparation of his thesis, he occupied a position of Associate Assistant in the Laboratory of Toxicology (2 years) and in the Laboratory of Pharmacokinetics (2 years) at the Faculty of Pharmacy of Marseille. He was then a postdoctoral fellow in the Department of Experimental Pharmacokinetics and Metabolism at HOFFMANN-LA ROCHE Laboratories in Basel (Switzerland) for two years. He was appointed in 1993 as Associate Assistant Professor in the Laboratory of Bromatology at the Faculty of Pharmacy of Marseille. In 1994, he was appointed as full Assistant Professor in the Laboratory of Pharmacokinetics and Clinical Pharmacy at the University of Bordeaux where his research was devoted to the development of in vitro pharmacokinetic/pharmacodynamic (PK/PD) models and their application to the study of the activity of different classes of drugs. Boubakar’s research has yielded 32 peer-reviewed publications.

Education

Pharm. D in 1982, University of Marseille, France

Ph. D in Pharmacology, Basic and Clinical Pharmacokinetic Option in 1988, University of Marseille, France.

Habilitation à Diriger les Recherches (HDR) in 2010, University of Bordeaux, France.

 

Direct responsability of granted projects :

Conseil Régional Aquitaine: 2001-2002

FEDER : 2001-2002

Found of the Oxford University : 2010

 

Research

Boubakar B. BA’s research was initially devoted to the development of an in vitro PK/PD model that allows more precise simulation of the PK profile (plasma or tissues) of antibiotics than most of the systems proposed in the literature. This model was then applied to investigate the effect of different classes of antibiotics on multi-resistant bacteria species as the multi-resistance has become a public health problem and requires the search for new therapeutic options. He intends to use the acquired know-how to develop similar models adapted to the study of other classes of drugs (antimalarials, antifungals (Call for Research Projects, ANSM 2017), anti-cancers, etc) or type of infection (bone infection treatment). He also collaborates within the ChembioPharm Team, to pharmaceutical development of different classes of drugs.

 

5 publications related to the in vitro PK/PD model applications and to pharmaceutical development:

 

  1. Ba, B. B., H. Feghali, C. Arpin, M. C. Saux, and C. Quentin. 2004. Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. Antimicrob. Agents Chemother. 48:946-953.
  2. Ba, B. B., C. Arpin, C. Vidaillac, A. Chaussé, M. C. Saux, and C. Quentin. 2006. Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance. Antimicrob. Agents Chemother. 50:1931-1936.
  3. Ba, B.B., C. Arpin, B. Bikie Bi Nso, V. Dubois, M.C. Saux, and C. Quentin. 2010. Activity of linezolid in an in vitro pharmacokinetic-pharmacodynamic model using different dosages and Staphylococcus aureus and Enterococcus faecalis strains with and without a hypermutator phenotype. Antimicrob. Agents Chemother. 54:1443-1452.
  4. Kauss,T., A. Gaubert, C. Boyer, B. B. Ba, M. Manse, S. Massip, J-M. Leger, F. Fawaz, M. Lembege, J-M. Boiron, X. Lafarge, N. Lindegardh, N.J. White, P. Olliaro, P. Millet, K. Gaudin. 2013. Pharmaceutical development and optimization of azithromycin suppository for paediatric use, Int. J. Pharm. 441:218-226.
  5. Gaubert, A., T. Kauss, M. Marchivie, B. B. Ba, M. Lembege, F. Fawaz, J-M. Boiron, X. Lafarge, N. Lindegardh, J-L. Fabre, N.J. White, P. Olliaro, P. Millet, K. Gaudin, 2014. Preliminary pharmaceutical development of antimalarial – antibiotic cotherapy as a pre-referral paediatric treatment of fever in malaria endemic areas. Int. J. Pharm., 468:55–63.

 

 

1 book:

Ba, B.B. Modèle Pharmacocinétique/Pharmacodynamique in vitro. Développement et Applications aux Anti-infectieux. Presses Académiques Francophones, Saarbrüken, Deutschland, 2014.

Category
Permanent researchers